ArticleFrontiers in immunology2026
Multi-omics analysis of kidney renal cell carcinoma in silico with preliminary
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Kidney renal clear cell carcinoma (KIRC) has a poor clinical prognosis, and its tumor progression and immunotherapy response are closely associated with genomic aberrations and immune microenvironment disorders. This study aimed to identify key prognostic biomarkers and potential therapeutic targets for KIRC via multi-omics integrative analysis and preliminary experimental validation. Methods: Multi-omics data including transcriptome, methylation, copy number variation (CNV), and immune infiltration data of KIRC were integrated from public databases, and further validated by single-cell RNA sequencing (scRNA-seq), two-sample Mendelian randomization (TSMR), in silico gene knockout, and quantitative PCR (qPCR). Results: Results demonstrated that CRHBP was a core downregulated prognostic biomarker in KIRC, with stage-dependent low expression and favorable survival predictive value (OS HR = 0.42, 95%CI: 0.395-0.45, P<0.05). ScRNA-seq revealed a compartmentalized CRHBP expression pattern and its differential regulation by immune checkpoint blockade (ICB) treatment and gender. TSMR confirmed the causal risk effect of testicular-derived UCN2 on KIRC, and UCN2 negatively correlated with tumor angiogenesis and hypoxia. Molecular docking screened dabrafenib as a promising candidate drug targeting CRHBP/UCN2 (binding affinity: -11.55/-17.23 kcal/mol). In silico knockout of CRHBP altered SRGN/TYROBP expression and inhibited cytokine production. QPCR verified decreased CRHBP expression in human KIRC tissues and elevated UCN2 expression in mouse KIRC tissues. Conclusions: The CRHBP-UCN2 axis critically regulates KIRC prognosis and immune microenvironment remodeling. CRHBP serves as a reliable prognostic biomarker and a potential anticancer peptide target, while dabrafenib is a promising therapeutic agent for KIRC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.